Ocumension Therapeutics (1477.HK) stock price, financials & research

Regular session · HKT · Market data may be delayed.

Company profile

Based in the People's Republic of China, Ocumension Therapeutics functions as a dedicated ophthalmic pharmaceutical platform. This company, along with its subsidiaries, is committed to the research, progression, and market introduction of therapeutic solutions for individuals with various eye conditions. Its extensive product offerings target treatments for disorders such as blepharitis, infectious and allergic conjunctivitis, dry eye syndrome, cataracts, glaucoma, ocular hypertension, post-surgical inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, corneal graft rejection, myopia, and optic neuritis. By December 31, 2021, Ocumension Therapeutics boasted a pipeline of 20 drug assets. The company, founded in 2017, maintains its headquarters in Suzhou, China.

Industry: Biotechnology
Sector: Healthcare
Headquarters: CN
CEO: Ye Liu
Listed since: Jul 10, 2020
Employees: 552

Market position

Day range

Current HK$5.10

HK$5.005HK$5.34

52-week range

Current HK$5.10

HK$4.04HK$11.08

Open: HK$5.34
Previous close: HK$5.285
Volume: 569.5K; 0.54× average
Average volume: 1.05M; Average daily volume
Market cap: 4.1B HKD
Beta: 0.43; Market reference 1
50-day average: HK$5.1917; -1.77% below average
200-day average: HK$6.8463; -25.51% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 5.04B CNY
EV / EBITDA: -168.4×
Earnings yield: -3.02%
Free cash flow yield: -6.82%

Profitability & efficiency

Return on equity: -4.31%
Return on assets: -3.88%
Return on invested capital: -4.11%

Financial health

Current ratio: 3.7×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

804.35M CNY+92.75%

Operating income

−160.2M CNY+47.72%

Net income

−158.82M CNY+40.80%

Metric (CNY)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	804.35M CNY	417.31M CNY	246.37M CNY	158.96M CNY	56.15M CNY
Cost of goods sold	443.43M CNY	192.24M CNY	102M CNY	56.04M CNY	19.21M CNY
Gross profit	360.92M CNY	225.07M CNY	144.37M CNY	102.92M CNY	36.94M CNY
Research and development	75.08M CNY	113.94M CNY	123.77M CNY	184.31M CNY	169.06M CNY
Selling, general, and administrative	446.05M CNY	270.99M CNY	279.01M CNY	373.79M CNY	253.81M CNY
Operating expenses	521.13M CNY	529.14M CNY	546.51M CNY	558.78M CNY	422.48M CNY
Interest income	6.23M CNY	22.22M CNY	21.92M CNY	28.22M CNY	26.89M CNY
Interest expense	2.38M CNY	2.16M CNY	1.33M CNY	1.79M CNY	567K CNY
Depreciation and amortization	130.25M CNY	77.07M CNY	57.54M CNY	40.46M CNY	9.62M CNY
Operating income	−160.2M CNY	−306.43M CNY	−402.15M CNY	−455.86M CNY	−385.2M CNY
Net income	−158.82M CNY	−268.27M CNY	−379.79M CNY	−402.64M CNY	−259.99M CNY